非小细胞肺癌免疫检查点抑制剂相关肺炎发生的危险因素
CSTR:
作者:
作者单位:

(1. 解放军医学院,北京 100853;2. 中国人民解放军总医院第二医学中心老年医学科,北京 100853)

作者简介:

通讯作者:

中图分类号:

基金项目:

解放军总医院国家老年疾病临床医学研究中心课题(NCRCG-PLAGH-DX-2024001)


Risk factors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
Author:
Affiliation:

(1. Medical School of Chinese PLA, Beijing 100853, China;2. Department of Geriatrics, Second Medical Centre, Chinese PLA General Hospital, Beijing 100853, China)

Fund Project:

This work was supported by the Project of National Clinical Research Center for Geriatric Diseases of Chinese PLA General Hospital(NCRCG-PLAGH-DX-2024001).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨免疫检查点抑制剂相关肺炎(ICI-P)发生的危险因素及预后,为有效防治提供策略。方法 回顾性分析2018年1月至2023年9月在中国人民解放军总医院接受免疫治疗的753例非小细胞肺癌患者的临床资料,根据是否发生ICI-P,将患者分为ICI-P组(102例)与非ICI-P组(651例),比较两组患者的临床特征;根据ICI-P的严重程度,将ICI-P患者分为轻度组(69例)和重度组(33例),对两组进行生存分析。采用SPSS 27.0统计软件进行数据分析。根据数据类型,分别采用t检验,Mann-Whitney U检验或χ2检验进行组间比较。采用logistic回归模型分析ICI-P发生的危险因素。采用Kaplan-Meier法评估轻度组和重度组的总生存期(OS),并采用Log-rank检验对两组患者的生存期进行比较。结果 ICI-P发生率为13.5%(102/753)。间质性肺病(ILD) (OR=3.85,95%CI 1.99~7.46;P<0.001)、胸部放疗史(OR=2.65,95%CI 1.56~4.48;P<0.001)、同期胸部放疗(OR=3.56,95%CI 1.69~7.47;P<0.001)及使用程序性死亡受体-1(PD-1)抑制剂(OR=3.54,95%CI 1.05~11.98;P=0.04)为ICI-P的独立危险因素。轻度组预期OS为927 d,重度组为573 d,差异有统计学意义(P=0.033)。结论 ILD、既往或同期胸部放疗及使用PD-1抑制剂是ICI-P发生的危险因素,治疗前对ILD及有胸部放疗史的患者进行重点评估、避免同步放疗是预防ICI-P的可行策略。

    Abstract:

    Objective To study the risk factors and prognosis of immune checkpoint inhibitor-related pneumonitis ( ICI-P) and provide effective strategies for its prevention and treatment. Methods A retrospective investigation was conducted of the medical record of 753 non-small cell lung cancer cases treated with immune checkpoint inhibitors (ICIs) at Chinese PLA General Hospital from January 2018 to September 2023. According to whether or not ICI-P occurred, the patients were divided into ICI-P group (102 cases) and non-ICI-P group (651 cases), and the clinical characteristics of the two groups were compared. According to severity of ICI-P, the patients with ICI-P were divided into a mild group (69 cases) and severe group (33 cases), and survival analysis was performed for the two groups. t test, Mann-Whitney U test orχ2 test was used for comparison between groups. Logistic regression analyses were employed to determine the risk factors of ICI-P. Kaplan-Meier method was used to calculate the overall survival (OS) for the mild and severe groups, and Log-rank test was used to compare the survival of the two groups. Results The incidence of ICI-P was 13.5% (102/753). Its independent risk factors included interstitial lung disease (ILD) (OR=3.85,95%CI 1.99-7.46; P<0.001), history of chest radiotherapy (OR=2.65,95%CI 1.56-4.48; P<0.001), concurrent chest radiotherapy (OR=3.56,95%CI 1.69-7.47; P<0.001) and the use of programmed cell death 1 (PD-1) inhibitors (OR=3.54,95%CI 1.05-11.98; P=0.04). The expected OS of the mild group was 927 d against 573 d in the severe group, and the difference was statistically significant (P=0.033). Conclusion ILD, prior or concurrent chest radiotherapy and the use of PD-1 inhibitors are risk factors of ICI-P. Focusing on the assessment of patients with ILD and a history of chest radiotherapy before treatment and avoiding concurrent radiotherapy are feasible strategies for preventing ICI-P.

    参考文献
    相似文献
    引证文献
引用本文

程琨翔,崔琳虹,崔明新,李小梅.非小细胞肺癌免疫检查点抑制剂相关肺炎发生的危险因素[J].中华老年多器官疾病杂志,2025,24(8):611-616
DOI:10.11915/j. issn.1671-5403.2025.08.132

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-10-08
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-08-25
  • 出版日期:
文章二维码